Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.
about
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.Probiotics and medical nutrition therapySystematic review and meta-analysis of Saccharomyces boulardii in adult patientsProbiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparationsAssessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous floraThe use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American expertsDevelopment of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agentReview of conventional and novel food processing methods on food allergens.The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trialSpecies identification and virulence attributes of Saccharomyces boulardii (nom. inval.).Use of luciferase genes as biosensors to study bacterial physiology in the digestive tractEffect of lactic acid bacteria on diarrheal diseases.Probiotic agents and infectious diseases: a modern perspective on a traditional therapy.Survival, physiology, and lysis of Lactococcus lactis in the digestive tractSertaconazole: pharmacology of a gynecological antifungal agent.A non-dairy probiotic's (poi) influence on changing the gastrointestinal tract's microflora environment.Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.Probiotics in the gastrointestinal diseases of the elderly.Treatment of Clostridium difficile-associated diarrhea.Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events.Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.Biotherapeutic agents and vaginal health.Taxonomic and strain-specific identification of the probiotic strain Lactobacillus rhamnosus 35 within the Lactobacillus casei group.Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii.Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells.Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis.Adhesion of Lactobacilli and their anti-infectivity potential.Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.The underuse of probiotics by family physicians.Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study.Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy.Inhibitory effect of Lactobacillus acidophilus on Helicobacter hepaticus in vitro.Use of the DNA sequence of variable regions of the 16S rRNA gene for rapid and accurate identification of bacteria in the Lactobacillus acidophilus complex.The use of konjac glucomannan hydrolysates to recover healthy microbiota in infected vaginas treated with an antifungal agent.Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients.
P2860
Q24529831-C8F6B851-EC84-40D8-A4D5-D6D01B34E628Q24548441-9AC44F92-AEAD-43E1-A301-ED0279D01152Q24621081-C57DF1E5-60CF-4255-BFDA-367816AE3ACEQ24679315-C9116DAA-7372-4789-8912-E91F877B3FF3Q24791618-415F6624-E7CF-4DDF-89F7-F91A91091FD8Q26823347-6F57BAF6-D837-4479-BA2A-1AE67162391BQ26991504-51A85619-EA5D-4C1C-A9AA-323018806CDCQ30381258-F84A10CA-15A1-417F-BEC9-B173770D2B6AQ33596735-DCF8D74B-C19A-4BDF-ABBE-5B3B673E6766Q33682695-6704E62B-EE30-42C2-87CF-634D87C27C26Q33715490-FF1F3CBB-CC80-4EFC-8AF0-5425E3AB5D71Q33887948-3B9BFB9A-7C58-4747-896F-19B550B30B12Q33945722-498286B8-7517-4055-9827-2AF1B2C6187CQ33985970-F5F0C942-5335-44D4-B405-DD742B67D557Q34105401-899483B5-F0D1-4AE4-A641-221C37E67385Q34345116-B0BC6FDF-19A0-452D-9A59-B2C05208F3ACQ34525343-091D8131-CE0D-46FF-8A4F-8A8E0025FBC1Q34637436-A1C8D123-1818-45B2-93CF-F0E6222F6E27Q34979678-40AE620B-6C08-45C9-90B5-D6EBDF6D6867Q35137168-4A440F51-2208-492E-A519-B063F2A2AA6AQ35270823-8003808D-7E54-493A-9C7E-82495B227644Q35540167-944B5080-A5AC-4C96-955D-49377BCAF499Q35635810-3E23DCF3-4781-4771-873C-E5FE352FB178Q35891684-07529C45-6148-4A89-8653-095D29BBFCC7Q36672610-A990B40D-17F8-4F0C-A0AC-1521D37DBC5DQ36862309-2AD20E92-2162-4D61-96BA-C6614EAF1686Q39519683-6372E6B2-B013-42F9-8B98-64EE37C2E0B4Q39536940-D31655A9-F2D2-466C-BBCE-73956E29F1A4Q40260363-8D163109-920A-4228-9393-7A0EDF36655AQ41328596-24AE7D7B-035D-4C2D-BDC3-F188DE143AD3Q41876318-E64BE8E5-5D56-46DB-9855-CF3BE7C39EECQ42721478-3627629A-EBEA-41F1-9277-1DDF0C214661Q43407358-9B47150A-F941-4FF6-A2FD-C8D4B6B38383Q44200362-5676494A-D2C6-4B29-99DA-E47C832E3091Q44373362-1B26F49E-759C-473A-90E4-ACB6E35A5B91Q44874126-29DC593D-48E8-4B27-9DC8-D94CAACFCD6DQ51358928-D1771FEE-749B-4C78-B446-BEF02D6D9FF4Q52140136-D02A6D36-7739-4AA2-AD19-2234D325D81C
P2860
Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Biotherapeutic agents. A negle ...... stinal and vaginal infections.
@en
type
label
Biotherapeutic agents. A negle ...... stinal and vaginal infections.
@en
prefLabel
Biotherapeutic agents. A negle ...... stinal and vaginal infections.
@en
P2093
P1476
Biotherapeutic agents. A negle ...... stinal and vaginal infections.
@en
P2093
C M Surawicz
L V McFarland
P304
P356
10.1001/JAMA.1996.03530350052034
P407
P577
1996-03-01T00:00:00Z